Physician characteristics and variability of erythropoiesis-stimulating agent use among Medicare patients with cancer.
about
Cytokine use and survival in the first-line treatment of ovarian cancer: a Gynecologic Oncology Group StudyComparative effectiveness of upfront treatment strategies in elderly women with ovarian cancerContraindicated use of bevacizumab and toxicity in elderly patients with cancerAdequacy of the National Quality Forum's Colon Cancer Adjuvant Chemotherapy Quality Metric: Is 4 Months Soon Enough?Use and duration of chemotherapy and its impact on survival in early-stage ovarian cancer.Gonadotropin-releasing hormone agonist overuse: urologists' response to reimbursement and characteristics associated with persistent overusePatterns of care, predictors, and outcomes of chemotherapy in elderly women with early-stage uterine carcinosarcoma: a population-based analysis.Triggers of hospitalization for venous thromboembolism.Patterns of use of hemostatic agents in patients undergoing major surgery.Trends in Periodic Surveillance Testing for Early-Stage Uterine Cancer Survivors.Deviations from guideline-based therapy for febrile neutropenia in cancer patients and their effect on outcomesComparative Effectiveness of Minimally Invasive Hysterectomy for Endometrial Cancer.Patterns of erythropoiesis-stimulating agent use among Medicare beneficiaries with myelodysplastic syndromes and consistency with clinical guidelines.Erythropoietin-stimulating agents and clinical outcomes in metastatic breast cancer patients with chemotherapy-induced anemia: a closed debate?Effects of the US Food and Drug Administration Boxed Warning of Erythropoietin-Stimulating Agents on Utilization and Adverse Outcome.Hemoglobin levels triggering erythropoiesis-stimulating agent therapy in patients with cancer: the shift after United States Food and Drug Administration policy changes.Adherence to treatment recommendations and outcomes for women with ovarian cancer at first recurrence.
P2860
Q30416045-A354E9E7-EB90-49FF-AE23-201B60255756Q33774527-58CED53A-C405-4C07-96DF-E4D09B67D7A1Q34368413-8A9C78A8-6E2D-4EF3-B5BF-AAF50DF2F0B2Q35133471-A78F09F4-4DB3-4227-81AF-4C55A6AECD7DQ35589020-19AC75F8-8380-4433-AE26-1E4A8B5866E2Q35602510-EE90F206-228D-4090-BE5E-0F9D8944DA83Q35849504-259CBC50-429E-475C-881A-2C60D0D7E720Q35929871-8FF55D78-F353-4F29-B591-E6C80528C6E4Q36137393-035D4500-D8FA-453C-BACB-66DE6D33F55DQ36609765-EE211B4A-FE66-4B91-BD15-6D08348B16CCQ36907218-82FF9916-2CF7-4EB2-B185-F05BBF3B9706Q36914426-D887A53F-CEAA-4D0F-AC63-7E66A1EACEC0Q36960399-9625EBEB-659A-4700-9FA0-680E02807E4AQ38189738-B7CFBBD6-DEA6-4E61-B28B-8A5CBE342B34Q38691137-F8F0BAE7-EC28-427D-9373-9BA0B15920B8Q44420464-2A0A7BA0-1195-4306-AB4A-2CFED2184AF4Q49887274-E38E1A49-A40D-4589-A329-E0CDB22DC9F5
P2860
Physician characteristics and variability of erythropoiesis-stimulating agent use among Medicare patients with cancer.
description
2011 nî lūn-bûn
@nan
2011 թուականի Օգոստոսին հրատարակուած գիտական յօդուած
@hyw
2011 թվականի օգոստոսին հրատարակված գիտական հոդված
@hy
2011年の論文
@ja
2011年論文
@yue
2011年論文
@zh-hant
2011年論文
@zh-hk
2011年論文
@zh-mo
2011年論文
@zh-tw
2011年论文
@wuu
name
Physician characteristics and ...... Medicare patients with cancer.
@ast
Physician characteristics and ...... Medicare patients with cancer.
@en
type
label
Physician characteristics and ...... Medicare patients with cancer.
@ast
Physician characteristics and ...... Medicare patients with cancer.
@en
prefLabel
Physician characteristics and ...... Medicare patients with cancer.
@ast
Physician characteristics and ...... Medicare patients with cancer.
@en
P2093
P2860
P356
P1476
Physician characteristics and ...... Medicare patients with cancer.
@en
P2093
Alfred I Neugut
Donna L Buono
Elizabeth T Wilde
Jason D Wright
Jennifer Malin
Wei Y Tsai
P2860
P304
P356
10.1200/JCO.2010.34.5462
P407
P577
2011-08-01T00:00:00Z